Regcell raised $66 million, including Japanese government support, to advance its regulatory T-cell platform toward clinic testing. The company plans to convert disease-driving immune cells into antigen-specific Tregs using an epigenetic reprogramming approach tied to Nobel-recognized biology. In another immunology move, Kymera Therapeutics disclosed new STAT6-targeting PROTACs positioned for multiple inflammatory and oncology indications. The disclosures expand the growing toolkit of targeted protein degradation into defined signaling nodes. Both updates underscore how the industry is refining immune modulation and precision targeting—either by reprogramming immune cell fate or by degrading central immune drivers to overcome resistance and improve specificity.